Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-47357
Andus, T; Kocjan, A; Müser, M; Baranovsky, A; Mikhailova, T L; Zvyagintseva, T D; Dorofeyev, A E; Lozynskyy, Y S; Cascorbi, I; Stolte, M; Vieth, M; Dilger, K; Mohrbacher, R; Greinwald, R (2010). Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflammatory Bowel Diseases, 16(11):1947-1956.
|PDF - Registered users only|
BACKGROUND: Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day. The primary objective of this study was to show the noninferiority of once-daily administration of a novel 1 g mesalamine suppository versus thrice-daily administration of the 0.5 g mesalamine suppository.
METHODS: This was a single-blind (investigator-blinded), randomized, multicenter, comparative, Phase III clinical trial. Patients with mild to moderately active ulcerative proctitis inserted either one mesalamine 1 g suppository at bedtime or one mesalamine 0.5 g suppository thrice daily over a 6-week period. The primary endpoint was rate of remission (Disease Activity Index below 4).
RESULTS: In all, 354 patients were evaluable for safety and per-protocol analysis. The new regimen demonstrated noninferiority: The percentage of patients with remission was 87.9% for the once-daily 1 g mesalamine suppository and 90.7% for the thrice-daily 0.5 g mesalamine suppository. Each regimen resulted in prompt cessation of clinical symptoms (e.g., median time to ≤3 stools per day (all without blood): 5 days in the 1 g mesalamine once-daily and 7 days in the 0.5 g mesalamine thrice-daily group). Patients preferred applying suppositories once a day.
CONCLUSIONS: In active ulcerative proctitis the once-daily administration of a 1 g mesalamine suppository is as effective and safe, yet considerably more convenient, than the standard thrice-daily administration of a 0.5 g mesalamine suppository.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology|
|DDC:||610 Medicine & health|
|Deposited On:||03 Mar 2011 20:06|
|Last Modified:||27 Nov 2013 20:53|
|Citations:||Web of Science®. Times cited: 6|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page